Review



plasma ferritin concentration  (Randox)


Bioz Verified Symbol Randox is a verified supplier
Bioz Manufacturer Symbol Randox manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Randox plasma ferritin concentration
    Plasma Ferritin Concentration, supplied by Randox, used in various techniques. Bioz Stars score: 94/100, based on 51 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma ferritin concentration/product/Randox
    Average 94 stars, based on 51 article reviews
    plasma ferritin concentration - by Bioz Stars, 2026-05
    94/100 stars

    Images



    Similar Products

    plasma ferritin concentration  (Randox)
    94
    Randox plasma ferritin concentration
    Plasma Ferritin Concentration, supplied by Randox, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma ferritin concentration/product/Randox
    Average 94 stars, based on 1 article reviews
    plasma ferritin concentration - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    plasma concentrations  (Monobind)
    96
    Monobind plasma concentrations
    Plasma Concentrations, supplied by Monobind, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma concentrations/product/Monobind
    Average 96 stars, based on 1 article reviews
    plasma concentrations - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    plasma nefa concentrations  (Randox)
    96
    Randox plasma nefa concentrations
    Plasma Nefa Concentrations, supplied by Randox, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma nefa concentrations/product/Randox
    Average 96 stars, based on 1 article reviews
    plasma nefa concentrations - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    plasma p tau217 concentrations  (Fujirebio Inc)
    99
    Fujirebio Inc plasma p tau217 concentrations
    Lumipulse <t>plasma</t> <t>p‐tau217</t> measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau
    Plasma P Tau217 Concentrations, supplied by Fujirebio Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma p tau217 concentrations/product/Fujirebio Inc
    Average 99 stars, based on 1 article reviews
    plasma p tau217 concentrations - by Bioz Stars, 2026-05
    99/100 stars
    		  Buy from Supplier
    plasma 194 insulin concentrations  (ALPCO)
    95
    ALPCO plasma 194 insulin concentrations
    Lumipulse <t>plasma</t> <t>p‐tau217</t> measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau
    Plasma 194 Insulin Concentrations, supplied by ALPCO, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma 194 insulin concentrations/product/ALPCO
    Average 95 stars, based on 1 article reviews
    plasma 194 insulin concentrations - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    plasma testosterone concentrations  (Cayman Chemical)
    95
    Cayman Chemical plasma testosterone concentrations
    Lumipulse <t>plasma</t> <t>p‐tau217</t> measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau
    Plasma Testosterone Concentrations, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plasma testosterone concentrations/product/Cayman Chemical
    Average 95 stars, based on 1 article reviews
    plasma testosterone concentrations - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Lumipulse plasma p‐tau217 measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau

    Journal: Alzheimer's & Dementia

    Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

    doi: 10.1002/alz.71147

    Figure Lengend Snippet: Lumipulse plasma p‐tau217 measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau

    Article Snippet: Four experiments assessing the effects of varied pre‐analytical sampling conditions on relative plasma p‐tau217 concentrations were undertaken using both the Lumipulse and ALZpath assays.

    Techniques: Clinical Proteomics, Derivative Assay

    Relative change in concentration of plasma p‐tau217 across pre‐analytical sample handling conditions: (A) pre‐centrifugation delay at RT, (B) pre‐centrifugation delay at 2 to 8°C, (C) post‐centrifugation delay, (D) number of freeze–thaw cycles, compared to the baseline condition using the ALZpath and Lumipulse assays ( n = 10 per experiment, data presented as median ± IQR, dotted lines represent the lower and upper bounds of a 10% difference threshold from the baseline condition). IQR, interquartile range; p‐tau, phosphorylated tau; RT, room temperature

    Journal: Alzheimer's & Dementia

    Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

    doi: 10.1002/alz.71147

    Figure Lengend Snippet: Relative change in concentration of plasma p‐tau217 across pre‐analytical sample handling conditions: (A) pre‐centrifugation delay at RT, (B) pre‐centrifugation delay at 2 to 8°C, (C) post‐centrifugation delay, (D) number of freeze–thaw cycles, compared to the baseline condition using the ALZpath and Lumipulse assays ( n = 10 per experiment, data presented as median ± IQR, dotted lines represent the lower and upper bounds of a 10% difference threshold from the baseline condition). IQR, interquartile range; p‐tau, phosphorylated tau; RT, room temperature

    Article Snippet: Four experiments assessing the effects of varied pre‐analytical sampling conditions on relative plasma p‐tau217 concentrations were undertaken using both the Lumipulse and ALZpath assays.

    Techniques: Concentration Assay, Clinical Proteomics, Analytical Sample Preparation, Centrifugation